We are live on
!
Find out more
TCM
Tamarack Capital Management Portfolio holdings
AUM
$840M
1-Year Est. Return
19.47%
This Fund
S&P 500
This Quarter
Est. Return
+1.77%
1 Year Est. Return
+19.47%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$870M
AUM Growth
+$111M
(+15%)
Cap. Flow
+$114M
Cap. Flow
% of AUM
13.05%
Top 10 Holdings %
Top 10 Hldgs %
66.83%
Holding
47
New
8
Increased
18
Reduced
6
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PDCO
Patterson Companies, Inc.
PDCO
|
+$25.6M |
| 2 |
Becton Dickinson
BDX
|
+$24.2M |
| 3 |
Quest Diagnostics
DGX
|
+$22.2M |
| 4 |
Lantheus
LNTH
|
+$11.3M |
| 5 |
Bruker
BRKR
|
+$10.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$24.9M |
| 2 |
Inogen
INGN
|
+$18.2M |
| 3 |
DexCom
DXCM
|
+$14M |
| 4 |
Pfizer
PFE
|
+$13.6M |
| 5 |
KERX
Keryx Biopharmaceuticals Inc
KERX
|
+$12.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 56.95% |
| 2 | Technology | 1.93% |
| 3 | Industrials | 0.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$778B
| $124M | 14.2% |
600,000
+200,000
| +50% | +$42.1M |
|
|
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
| $82.3M | 9.47% |
400,000
| – | – |
|
3
PUT
iShares Russell 2000 ETF
IWM
$80.9B
| $62.4M | 7.18% |
500,000
+100,000
| +25% | +$12.5M |
|
|
ELGX
4
DELISTED
Endologix Inc
ELGX
| $62.1M | 7.14% |
405,000
+5,000
| +1% | +$825K |
|
|
5
Becton Dickinson
BDX
$43.1B
| $56.7M | 6.51% |
410,000
+175,275
| +75% | +$24.2M |
|
|
6
Quest Diagnostics
DGX
$25.1B
| $50.8M | 5.84% |
700,000
+300,000
| +75% | +$22.2M |
|
|
PDCO
7
DELISTED
Patterson Companies, Inc.
PDCO
| $41.6M | 4.78% |
855,000
+537,055
| +169% | +$25.6M |
|
8
Integer Holdings
ITGR
$3.35B
| $39M | 4.49% |
794,186
+164,584
| +26% | +$8.02M |
|
9
Medtronic
MDT
$107B
| $37M | 4.26% |
500,000
+125,000
| +33% | +$9.55M |
|
10
Alkermes
ALKS
$8.82B
| $25.7M | 2.96% |
400,000
+160,000
| +67% | +$9.79M |
|
|
MDRX
11
DELISTED
Veradigm Inc. Common Stock
MDRX
| $24.3M | 2.79% |
1,775,000
+275,000
| +18% | +$3.71M |
|
|
SPNC
12
DELISTED
Spectranetics Corp
SPNC
| $24.2M | 2.78% |
1,050,000
-27,596
| -3% | -$771K |
|
|
NXTM
13
DELISTED
NxStage Medical Inc.
NXTM
| $23.9M | 2.75% |
1,675,000
+375,000
| +29% | +$6.35M |
|
14
AtriCure
ATRC
$1.77B
| $21.8M | 2.51% |
885,000
+85,000
| +11% | +$1.9M |
|
15
Bio-Rad Laboratories Class A
BIO
$8.42B
| $18.2M | 2.1% |
121,050
+13,050
| +12% | +$1.87M |
|
|
LMNX
16
DELISTED
Luminex Corp
LMNX
| $17.3M | 1.98% |
1,000,000
+366,908
| +58% | +$6.15M |
|
|
IMPR
17
DELISTED
IMPRIVATA, INC COM
IMPR
| $16.8M | 1.93% |
1,025,000
+595,739
| +139% | +$8.94M |
|
18
MiMedx Group
MDXG
$626M
| $15.1M | 1.73% |
1,300,000
+300,000
| +30% | +$3.09M |
|
|
SRGA
19
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $12.9M | 1.49% |
66,667
| – | – |
|
|
CTRX
20
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
| $11.6M | 1.33% |
189,802
-60,198
| -24% | -$3.61M |
|
|
21
Lantheus
LNTH
$6.82B
| $11M | 1.26% |
+1,770,918
| New | +$11.3M |
|
|
22
Bruker
BRKR
$9.2B
| $10.2M | 1.18% |
+500,709
| New | +$10.1M |
|
23
ICU Medical
ICUI
$3.93B
| $10.1M | 1.16% |
105,776
+70,776
| +202% | +$6.61M |
|
|
CORI
24
DELISTED
Corium International, Inc.
CORI
| $9.85M | 1.13% |
719,385
-59,536
| -8% | -$672K |
|
25
CALL
Perrigo
PRGO
$1.4B
| $9.8M | 1.13% |
+53,000
| New | +$10.1M |
|
Similar funds
RI
CWA
GHF
F
TRV
BMCMI
GACM
AH
Tamarack Capital Management's Q2 2015 Portfolio in Review
As of Q2 2015, Tamarack Capital Management held 47 positions worth $870M, up 15% from $759M the previous quarter. Its ten largest holdings account for 67% of the portfolio.
Tamarack Capital Management deployed $114M of net new capital in Q2 2015, opening 8 new positions and adding to 18 existing holdings. Its largest new stake was Lantheus: 1,770,918 shares worth $11M.
By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 58% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Inogen, an estimated $18.2M trimmed.
- Tamarack Capital Management's largest Q2 2015 buy was Lantheus: 1,770,918 shares worth $11M.
- Tamarack Capital Management added most to Patterson Companies, Inc. in Q2 2015, an estimated $25.6M increase.
- Tamarack Capital Management's biggest Q2 2015 reduction was Inogen, cutting an estimated $18.2M.
- Tamarack Capital Management fully exited Teva Pharmaceuticals in Q2 2015, selling an estimated $24.9M.
- Tamarack Capital Management's ten largest holdings make up 67% of its $870M portfolio in Q2 2015.
- Tamarack Capital Management opened 8 new positions and closed 12 in Q2 2015.
- Tamarack Capital Management's portfolio value rose 15% quarter-over-quarter to $870M.
Based on Tamarack Capital Management's 13F filing for Q2 2015, filed 11 Aug 2015.